Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6588597 | 0.91 | HRH3 (0.66) | HRH3KDM4EALDH1A1SMN1; SMN2KEAP1 | |
| SCHEMBL14606842 | 0.85 | HRH3 (0.65) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL9671156 | 0.83 | KDM4E (0.83) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL18464818 | 0.82 | HRH3 (0.61) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL12088667 | 0.82 | SMN1; SMN2 (0.56) | KDM4EALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL272824 | 0.81 | ALDH1A1 (0.62) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL12359378 | 0.80 | HRH3 (0.73) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| Hydrochloric Acid SCHEMBL5693237 | 0.79 | ALDH1A1 (0.61) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL110784 | 0.79 | KEAP1 (0.83) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL3260775 | 0.79 | HRH3 (0.71) | HRH3KDM4EALDH1A1SMN1; SMN2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329911-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100063096-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-7642355-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(5-[4-(3-dimethylaminopropoxy)benzylamino]pentylcarbamoyl)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1866284-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006099167-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | HRH3 87/4885KDM4E 2416/4885ALDH1A1 1128/4885 |
| US-20100063096-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | HRH3 87/4885KDM4E 2416/4885ALDH1A1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.